Safety and Efficacy of RM-001 (Autologous HBG1/2 Promoter-modified CD34+Hematopoietic Stem and Progenitor Cells) in Patients with Transfusion-Dependent Thalassemia

BLOOD(2023)

Cited 0|Views11
No score
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined